Monitor Atossa's regulatory progress on (Z)-endoxifen for Duchenne muscular dystrophy and McCune-Albright syndrome — FDA approval of a qualifying marketing application is the prerequisite for any CVR payment. The rare pediatric disease PRV program sunset on September 30, 2029 creates a hard deadline for approval. No trading catalyst exists until a PRV is awarded and monetized.
Price Chart
Executive Summary
Atossa Therapeutics entered into a Contingent Value Rights (CVR) Agreement, declaring a dividend of one CVR per share of common stock outstanding as of October 19, 2026. The CVRs entitle holders to 25% of net proceeds from the monetization of the company's first qualifying FDA priority review voucher (PRV), capped at $50 million. However, no product candidate has been approved, no marketing application has been submitted, and no PRV has been awarded — the CVRs are purely contingent on future, uncertain regulatory outcomes.
Key Facts
- One CVR declared per share of common stock outstanding as of October 19, 2026 record date.
- CVR holders entitled to 25% of net proceeds from sale or deemed monetization of first qualifying FDA priority review voucher.
- Aggregate CVR payments capped at $50 million.
- Qualifying voucher must be awarded on or before December 31, 2036 (Outside Date), extendable by Board.
- No product candidate has been approved by the FDA; no marketing application submitted for (Z)-endoxifen for DMD or MAS.
- No priority review voucher has been awarded to the company.
- Company retains sole discretion over development, regulatory strategy, and whether to sell or use any voucher.
- CVRs are stapled to common stock and not separately tradeable unless Board elects detachment.
- Payments may be deferred if they would render the company insolvent or violate Delaware law; deferred payments terminate if unpaid after 24 months.
- Rare pediatric disease PRV program is scheduled to sunset on September 30, 2029.
Financial Impact
Up to $50 million aggregate potential payment to shareholders, representing 25% of net proceeds from a future PRV monetization. No current financial impact as no PRV has been awarded.
Risk Factors
- No product candidate has been approved by FDA for any indication.
- No marketing application has been submitted for (Z)-endoxifen for DMD or MAS.
- PRV program sunset on September 30, 2029 — approval must occur before sunset for voucher eligibility.
- Company has no obligation to develop, seek approval, or monetize any voucher.
- Payments subject to $50 million cap, solvency limitations, and potential 24-month deferral termination.
- CVRs may never be detached or trade separately, limiting liquidity for holders.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-418560 |
| Document: atos-20261008.htm | 0001193125-26-418560 |
| Document: atos-ex99_1.htm | 0001193125-26-418560 |
| Document: 0001193125-26-418560-index-headers.html | 0001193125-26-418560 |
| Document: 0001193125-26-418560-index.html | 0001193125-26-418560 |
| Document: 0001193125-26-418560.txt | 0001193125-26-418560 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $2.44 | awaiting T+60 | — | $2.38 (−2.46%) |
Sep 29, 2026 28d ago | 8-K | $1.99 | awaiting T+60 | — | $2.38 (+19.60%) |
Sep 18, 2026 5w ago | 8-K | $2.25 | awaiting T+60 | — | $2.38 (+5.78%) |
Aug 7, 2026 11w ago | 8-K | $2.36 | awaiting T+60 | — | $2.38 (+0.85%) |
Aug 7, 2026 11w ago | Press Release | $2.36 | awaiting T+60 | — | $2.38 (+0.85%) |
Jun 12, 2026 19w ago | 424B5 | $2.46 $2.52 | ▼ −2.24% | ▲ +1.03% | $2.38 (+3.25%) |
Apr 16, 2026 27w ago | 8-K | $5.77 $2.40 | ▼ −58.41% | ▼ −65.45% | $2.38 (−58.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers